Fig. 4

Grouping of statins by intensity categories according to the percentage reduction in low-density lipoprotein [21]. *Advice from the MHRA (Medicines and Healthcare products Regulatory Agency): there is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80 mg dose should be considered only in patients with severe hypercholesterolemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks